Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland

Gudmundur L. Norddahl, Pall Melsted, Kristbjorg Gunnarsdottir, Gisli H. Halldorsson, Thorunn A. Olafsdottir, Arnaldur Gylfason, Mar Kristjansson, Olafur T. Magnusson, Patrick Sulem, Daniel F. Gudbjartsson, Unnur Thorsteinsdottir, Ingileif Jonsdottir and Kari Stefansson ()
Additional contact information
Gudmundur L. Norddahl: deCODE genetics/Amgen, Inc.
Pall Melsted: deCODE genetics/Amgen, Inc.
Kristbjorg Gunnarsdottir: deCODE genetics/Amgen, Inc.
Gisli H. Halldorsson: deCODE genetics/Amgen, Inc.
Thorunn A. Olafsdottir: deCODE genetics/Amgen, Inc.
Arnaldur Gylfason: deCODE genetics/Amgen, Inc.
Mar Kristjansson: Landspitali—The National University Hospital of Iceland
Olafur T. Magnusson: deCODE genetics/Amgen, Inc.
Patrick Sulem: deCODE genetics/Amgen, Inc.
Daniel F. Gudbjartsson: deCODE genetics/Amgen, Inc.
Unnur Thorsteinsdottir: deCODE genetics/Amgen, Inc.
Ingileif Jonsdottir: deCODE genetics/Amgen, Inc.
Kari Stefansson: deCODE genetics/Amgen, Inc.

Nature Communications, 2022, vol. 13, issue 1, 1-10

Abstract: Abstract By the end of July 2021, the majority of the Icelandic population had received vaccination against COVID-19. In mid-July a wave of SARS-CoV-2 infections, dominated by the Delta variant, spread through the population, followed by an Omicron wave in December. A booster vaccination campaign was initiated to curb the spread of the virus. We estimate the risk of infection for different vaccine combinations using vaccination data from 276,028 persons and 963,557 qPCR tests for 277,687 persons. We measure anti-Spike-RBD antibody levels and ACE2-Spike binding inhibitory activity in 371 persons who received one of four recommended vaccination schedules with or without an mRNA vaccine booster. Overall, we find different antibody levels and inhibitory activity in recommended vaccination schedules, reflected in the observed risk of SARS-CoV-2 infections. We observe an increased protection following mRNA boosters, against both Omicron and Delta variant infections, although BNT162b2 boosters provide greater protection against Omicron than mRNA-1273 boosters.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33076-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33076-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33076-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().